| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $58.4M | +9.2% |
| Cost of Revenue | $31.3M | +13.3% |
| R&D Expense | $5.6M | +5.5% |
| SG&A Expense | $45.2M | +70.5% |
| Operating Income | -$24.6M | -130.5% |
| Pre-tax Income | -$34.3M | -9.2% |
| Net Income | -$34.3M | -9.2% |
| EPS (Basic) | -$2.87 | -5.1% |
| EPS (Diluted) | -$2.87 | -5.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $13.0M | -20.2% |
| Short-term Investments | $5.0M | -19.2% |
| Accounts Receivable | $6.4M | +4.8% |
| Inventory | $21.5M | +88.3% |
| Current Assets | $46.8M | +11.4% |
| Total Assets | $71.4M | +7.7% |
| Current Liabilities | $40.6M | +170.4% |
| Total Liabilities |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$14.8M | -551.9% |
| Capital Expenditures | $83K | -46.8% |
| Investing Cash Flow | $1.3M | +159.4% |
| Financing Cash Flow | $10.3M | — |
| Free Cash Flow | -$14.9M | -513.5% |
| $83.7M |
| +75.6% |
| Stockholders' Equity | -$26.0M | -635.2% |